Winners of the Association of Community Cancer Centers 2022 Innovator Awards, presented at the National Oncology Conference, include a program to embed primary care in a cancer center and an effort to increase compliance with giving patients same-day medication education.
It’s important that patients are the healthiest they can be when going into treatment for cancer, emphasized Debra Delaney, MSN, FNP-BC, primary care nurse practitioner at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute.
Ochsner Health's program was among the recipients of the 2022 ACCC Innovator Awards, given to projects that improve patient care, are cost-effective, and are replicable.
New and emerging medications in the specialty drug pipeline were discussed during a keynote address at AMCP Nexus 2022 by Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, with biosimilars, orphan drugs, and cell and gene therapies emerging as key trends to watch.
A cross-sectional study found that severe anemia was common in patients with chronic kidney disease (CKD) and was associated with lower glomerular filtration rate (eGFR) and multiple adverse outcomes.
Much of artificial intelligence (AI) is now being used in the more mundane areas of health care, figuring out where to be most helpful, so doctors can do what they do best, which is diagnostic care, noted Scott Penberthy, PhD, MS, director, Applied AI, Office of the CTO, at Google.
William B. Miller, Jr, MD, evolutionary biologist, medical doctor, and author explains the importance of cellular research in finding inventive solutions to the growing burden of cancer.
A cohort study found that patients diagnosed with diabetes at a younger age were more at risk for adverse outcomes when compared with later diagnosis.
The FDA authorizes the COVID booster shots for children as young as 5; babies born during the pandemic may experience delayed communication skills compared with babies born prior; regulatory burden has increased for 89% of medical practices.
On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Kelly Price, US Head of Rare Disease at HRA Pharma, argues proving the value of the prescription digital therapeutic (PDT) market may lead to better coverage of PDTs.
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.
Kevin N. Astle, PharmD, assistant professor at University of South Florida Taneja College of Pharmacy, expands on HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline discussed at the Academy of Managed Care Pharmacy Nexus fall 2022 meeting.
Two stakeholders from Avalere Health discuss the utility of patient-centric value frameworks for equitable health care delivery, as well as challenges and strategies regarding its implementation at Academy of Managed Care Pharmacy Nexus 2022.
Patients with hepatitis C virus infection and chronic homelessness who were placed into permanent supportive housing exhibited a significantly reduced risk of hospitalization and liver-related morbidity and mortality.
Stakeholders at the Academy of Managed Care Pharmacy (AMCP) Nexus 2022 meeting review federal legislative and regulatory updates in managed care pharmacy and the impact that upcoming midterm elections will have on these provisions.
However, the researchers said their findings should not be interpreted as completely refuting the possibility that hydroxychloroquine might be a useful tool in preventing or slowing the development of systemic lupus erythematosus (SLE).
Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ NCSLC.
Despite the use of therapies to address the clinical manifestations of myelofibrosis (MF) and essential thrombocythemia (ET), the symptom burdens of these conditions continue to negatively affect patient quality of life (QOL).
Risk for individual hepatobiliary cancers varies from comorbidity to comorbidity, researchers found.
The bill was introduced by 2 Republicans and 2 Democrats and would direct HHS to undertake a study to understand how substitution of interchangeable biologic products may be impeded.
The study found that combined therapeutic strategies may help lower the risk.
A recent study evaluated the relationships between disturbed sleep and executive functioning, internal emotional distress, and worry related to school and sleep in adolescents.
Findings of a recent study suggest that complications of sickle cell disease (SCD) significantly contribute to morbidity and are more prevalent among older patients.
A search of the peer-reviewed literature turned up inconsistent findings on the effectiveness of corticosteroid irrigation for the treatment of chronic rhinosinusitis (CRS) with nasal polyps.
Families may see lower costs for health insurance through the Affordable Care Act (ACA); Walgreens Boots Alliance will take full ownership of CareCentrix; Bright Health will stop offering individual and family health insurance plans in 9 states.
Patients with atopic dermatitis reported that exposure to corticosteroid treatment throughout their lifetime put them at a risk for negative outcomes.
As with many medical meetings, some of the presentations from the annual American College of Chest Physicians event will be livestreamed or on demand for later viewing, but the organizers have stressed the importance of coming together for the first time since 2019.
CHEST 2022 is being held in Nashville, Tennessee, beginning October 16, and Subani Chandra, MD, FCCP, the chair of the Scientific Program Committee, discusses why meeting in real life as opposed to virtually is energizing, even if medical conferences are hectic.
There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.
